Cystic fibrosis (CF) is a multiorgan disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). In patients with CF, abnormalities initiate in several organs before birth. However, the long-term impact of these in utero pathologies on disease pathophysiology is unclear. To address this issue, we generated ferrets harboring a VX-770 (ivacaftor)-responsive CFTR G551D mutation. In utero VX-770 administration provided partial protection from developmental pathologies in the pancreas, intestine, and male reproductive tract. Homozygous CFTR G551D/G551D animals showed the greatest VX-770-mediated protection from these pathologies. Sustained postnatal VX-770 administration led to improved pancreatic exocrine function, glucose tolerance, growth and survival, and to reduced mucus accumulation and bacterial infections in the lung. VX-770 withdrawal at any age reestablished disease, with the most rapid onset of morbidity occurring when withdrawal was initiated during the first 2 weeks after birth. The results suggest that CFTR is important for establishing organ function early in life. Moreover, this ferret model provides proof of concept for in utero pharmacologic correction of genetic disease and offers opportunities for understanding CF pathogenesis and improving treatment.
INTRODUCTION
Cystic fibrosis (CF) is a recessive genetic disease caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel that moves chloride and bicarbonate across epithelia of many organs (1) . Patients with CF have greatly benefited from the discovery of small molecules that increase the amount and/or function of many mutant CFTR forms (2) . The two main classes of such drugs are potentiators and correctors, which rescue channel gating or processing defects in CFTR, respectively (2, 3) . Alone and in combination, these drugs have shown clinical benefit in an expanding number of CFTR genotypes (2, 4) . The best-characterized CFTR potentiator in people is VX-770 (ivacaftor), which restores channel gating of CFTR produced by CFTR G551D (5), a mutation found in 2 to 5% of patients with CF, as well as other mutant CFTR forms that produce mutant CFTR protein expression at the cell surface (6, 7) . VX-770 has been evaluated in children with CF as young as 2 years of age (8) and is now approved for use in people with CF with specific CFTR mutations who are 1 year of age and older.
Studies in younger patients are important because early CF manifestations may affect disease progression. For example, the loss of CFTR function impairs proper development of the vas deferens and epididymis, such that males with CF are almost always infertile (9) . In addition, gastrointestinal abnormalities and obstruction can occur before and after birth (10) , and destruction of the exocrine pancreas occurs in most people with CF within the first 2 years of life (11) .
These and other early consequences of CF substantially affect the growth and health of infants with this disease (11) . Despite intervention, growth of newborns with CF lags behind healthy controls within the first year of life (12) . This can have long-term consequences because impaired growth during the early postnatal period correlates with earlier lung infections in infants with CF (13) . Cumulatively, these and other findings suggest that CF disease starts in utero and affects postnatal health. Thus, it is very important to be able to study these early manifestations of CF to understand the pathogenesis of disease and the degree to which CFTR modulators may affect disease progression when administered early in life.
Animal models of CF offer a path to understand how CFTR function affects disease severity and progression in ways that would not be practical in humans. Although large animal models of CF such as the pig and the ferret mimic many aspects of early CF disease, mortality associated with gut and pancreatic abnormalities (14) (15) (16) has hindered their utility to study CF pathogenesis. Like infants with CF, CF ferrets are prone to meconium ileus (MI, gut obstruction at birth) and are particularly fragile during the neonatal period (16) . However, the incidence of MI in CF ferrets is ~4-to 5-fold greater than that of infants with CF (10, 16) . Despite numerous interventions that prevent gut obstruction and promote growth (elemental diet, stool softeners, pancreatic enzymes, and proton pump inhibitors) and inhibit lung infection (multiple antibiotics), CF ferrets grow slower than non-CF controls and have a higher rate of neonatal mortality (15) (16) (17) .
To address this limitation, we reasoned that in utero pharmacological rescue with a CFTR modulator could improve survival and also provide the basis for studying disease-relevant processes afforded by precise control of CFTR function. This would facilitate evaluation of the importance of CFTR function during fetal development and the early postnatal period while also enabling studies of longer-term disease progression. The ferret model was chosen because it manifests many aspects of CF intestinal, pancreatic, and lung disease (15) (16) (17) (18) and is modestly sized compared with the pig.
RESULTS

Generating a knock-in ferret harboring the CFTR
G551D allele We generated a knock-in ferret harboring the CFTR G551D allele and studied the effects of in utero and postnatal administration of the potentiator VX-770 on survival and CF-associated pathologies. To establish the CFTR G551D model, we used recombinant adeno-associated virus (rAAV)-mediated homologous recombination in fetal ferret fibroblasts, followed by somatic cell nuclear transfer ( fig. S1A ). This generated CFTR G551D/WT founders for which a clean homologous recombination event was confirmed by Southern blotting ( fig. S1B ), polymerase chain reaction (PCR; fig. S1C ), and sequencing ( fig. S1D) . A silent codon change at the target locus introduced a Bcl I restriction site for rapid genotyping ( fig. S1E) (Fig. 1B ). Short circuit current (I sc ) measurements on freshly excised intestine, from untreated CFTR WT/WT and CFTR G551D/G551D ferrets born to VX-770-treated jills, demonstrated that VX-770 treatment of CFTR G551D/G551D intestine produced a cyclic adenosine monophosphate (cAMP)-inducible chloride current ~28% that observed in CFTR WT/WT intestine, which was inhibited by the CFTR channel blocker GlyH101 (Fig. 1C and fig. S2E ). Polarized pancreatic ductal epithelium (PDE) generated from CFTR WT/WT , CFTR KO/KO , and CFTR G551D/G551D pancreata demonstrated similar results to that of intestine. CFTR G551D/G551D PDE cultures differentiated in the presence of VX-770 gave cAMP-inducible chloride currents averaging 29% that of CFTR WT/WT PDE cultures ( Fig. 1D and fig. S2F ). By contrast, CFTR G551D/G551D PDE cultures differentiated in the presence of vehicle (DMSO) demonstrated no cAMP-inducible or GlyH101-inhibitable chloride currents, similar to CFTR KO/KO PDE (Fig. 1D) . Thus, ferret CFTR G551D PDE retains little function to conduct chloride in the absence of VX-770.
Reduction of MI in CFTR
G551D ferrets treated in utero with VX-770 We next determined whether VX-770 could rescue the severe MI phenotype in the CF ferret model. Because most CF ferrets die at birth due to MI (~80%) (16), we chose to administer VX-770 to the pregnant jills during the gestational period of 42 days. We chose embryonic day 28 (E28) as the gestational time to start VX-770 administration because CFTR expression was abundant in both the intestine and pancreas at this time ( fig. S3, A to F) . This timing would be roughly equivalent to the start of the third trimester in humans. Pharmacokinetic experiments determined the VX-770 dose required to obtain human therapeutic concentrations of VX-770 in fetal tissues of pregnant wild-type jills (see Supplementary Materials and Methods). Administration of VX-770 from E28 to E42 led to a significantly greater fraction of CFTR G551D/KO kits (63%) and CFTR G551D/G551D kits (96%) passing meconium following birth, as compared to CFTR KO/KO kits (22%) (P = 1.14 × 10 6 ) ( Fig. 1 , E and F). In the absence of in utero VX-770 administration (no treatment or vehicle-treated), the percentage of CFTR G551D/KO and CFTR G551D/G551D kits passing meconium was not significantly different compared to that observed for untreated and vehicle-treated CFTR KO/KO ferrets ( Fig. 1 , E and F) (no treatment, P = 0.3992; vehicle, P = 0.5398). Survival of CFTR G551D/KO and CFTR G551D/G551D ferrets in the first month was also significantly enhanced over that of CFTR KO/KO ( Fig. 1G ) (G551D/KO, P = 0.0062; G551D/G551D, P < 0.0001). Cumulatively, these results demonstrated that the ferret CFTR G551D protein is responsive to VX-770, and when administered in utero, this CFTR potentiator can protect CF ferrets from MI.
In utero VX-770 protection of CFTR
G551D/G551D
male reproductive tract We then evaluated whether other in utero developmental abnormalities could be rescued by VX-770. More than 99% of human adult males with CF have congenital bilateral absence of the vas deferens, and some also have abnormalities in the tail and body of the epididymis (9) . Vas deferens abnormalities in newborn CFTR KO/KO ferret kits have been reported (16) , but the phenotype of the epididymis remains unknown. Here, we show that newborn CFTR KO/KO kits lacked not only the vas deferens but also the epididymis (Fig. 2,  A and B) . These developmental abnormalities were rescued only in CFTR G551D/G551D kits born to VX-770-treated jills, whereas there was no effect in vehicle-treated jills for CFTR G551D/G551D kits or vehicle-and VX-770-treated jills for CFTR G551D/KO kits ( and VX-770-treated CFTR G551D/G551D kits (Fig. 2 , G to L). Thus, unlike the partial rescue of MI by VX-770 in CFTR G551D/KO kits, the development of these male reproductive structures requires greater CFTR expression and function than provided in CFTR G551D/KO kits.
Restoration of growth and partial preservation of exocrine pancreas function in VX-770-treated CFTR G551D ferrets To determine the postnatal therapeutic effects of VX-770 administration, we established a dosing regimen based on pharmacokinetic experiments on young kits (see Supplementary Materials and Methods). We then evaluated the impact of VX-770 administration on animal growth and fecal elastase (EL-1) concentration as a measure of pancreatic function during the first several months of life. For CFTR G551D/G551D and CFTR G551D/KO kits reared on VX-770, growth rates were similar to those of wild-type animals and significantly (P < 0.001) higher than those of CFTR KO/KO kits (Fig. 3A) . Although the majority of VX-770-treated CFTR G551D/KO ferrets exhibited pancreatic insufficiency (PI) within the first month of life, they continued to grow at normal rates even without pancreatic enzyme supplementation while nursing (Fig. 3, A to C) . Moreover, the majority of VX-770-treated CFTR G551D/G551D ferrets maintained pancreatic sufficiency (PS) with EL-1 concentrations in the normal range; only one of eight animals exhibited Each point represents the AUC for five to seven independent experiments, each from independent donor animals. Data represent the means ± SEM. Significant differences were determined by two-way analysis of variance (ANOVA) and Bonferroni post hoc tests, **P < 0.01 and ***P < 0.001 for comparison of VX-770 to DMSO within a genotype, and # P < 0.1, ## P < 0.01, and ### P < 0.001 for comparison of VX-770 treatment groups across genotypes. There was no significant difference between any time points when comparing VX-770 to DMSO treatment groups for WT/WT and KO/KO groups. ANOVA P values for the significance of the VX-770 effect were WT/WT (P = 0.6471), KO/KO (P = 0.9569), G551D/KO (P < 0.0001), and G551D/G551D (P < 0.0001). (B) Percentage of the WT AUC swelling response for the indicated G551D genotypes and forskolin concentration. The two-way ANOVA P values for the significance of the genotype effect are given below the legend. The average KO/KO AUC over all time points was subtracted from WT and G551D genotypes before making this calculation. (C and D) I sc measurements on (C) freshly excised intestine at the level of the jejunum and (D) polarized PDE grown at an air-liquid interface. Shown are the changes in I sc (I sc ) in response to sequential addition of amiloride, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS), forskolin (FSK) and 3-isobutyl-1-methylxanthine (IBMX), and/or GlyH101 (CFTR inhibitor), as indicated for the given genotypes. Data represent the means ± SEM [n in graphs indicates independent measurements from three to four animals per genotype in (C) and independent cultures derived from three to four donor animals per genotype in (D)]. The order of genotypes in (D) from left to right is WT/WT, KO/KO, G551D/G551D + DMSO, and G551D/G551D + VX-770. Significant differences were determined by two-way ANOVA and Bonferroni post hoc tests; P > 0.05 [ns (not significant)], *P < 0.05, **P < 0.01, and **P < 0.001 for comparison between genotypes in (C) and for comparison to KO/KO in (D). (E) Representative images of intestine from neonatal kits of the indicated genotypes and treatment conditions with VX-770 or vehicle administration to jills at E28. Asterisks mark intestinal dilatation and arrows mark the point of intestinal obstruction. (F) Percentage of newborn kits passing meconium at birth. Starting at E28, pregnant jills were treated with VX-770, vehicle only, or left untreated. Numbers in parentheses represent births for each genotype evaluated. Fisher's exact test was used to assess differences between the following groups: (i) treatment groups across all genotypes: no treatment, P = 0.3992; vehicle, P = 0.5398; and VX-770, P = 1.14 × 10 ; and (iii) genotypes with VX-770 treatment: KO/KO versus G551D/KO, P = 9.70 × 10 −4 ; KO/KO versus G551D/G551D, P = 5.10 ×10 −7 ; and G551D/KO versus G551D/G551D, P = 5.84 × 10 −4 .
(G) Survival rates of kits after 1 week of age for the various genotypes. G551D genotypes were born to VX-770-treated jills and maintained on VX-770 after birth, whereas KO/KO genotypes were not treated with VX-770. Numbers in parentheses represent the number of kits in each group starting at 1 week of age. Log-rank (Mantel-Cox) test was used to assess significance of differences in survival between genotypes: KO/KO versus G551D/KO (P = 0.0062), KO/KO versus G551D/G551D (P < 0.0001), and G551D/KO versus G551D/G551D (P = 0.1186).
persistent PI, and this occurred during the third months of life ( Fig. 3 , B and C). The pancreatic histopathology observed at birth in untreated CFTR G551D/G551D and CFTR G551D/KO kits was similar to that in newborn CFTR KO/KO kits and involved luminal dilatation of the exocrine acini (Fig. 3D ). This pathology was largely prevented in CFTR G551D/G551D kits by in utero treatment with VX-770; the same was true, though to a lesser degree, for CFTR G551D/KO kits ( Fig. 3D ). Pancreatic histology of the pancreatic sufficient CFTR G551D/G551D ferrets was similar to that of CFTR WT/WT controls, both retaining the acinar cell compartment. By contrast, pancreatic insufficient CFTR G551D/KO and CFTR
ferrets were characterized by exocrine destruction and fibrosis resembling those observed in CFTR KO/KO ferrets (Fig. 3E ). Collectively, these results revealed that VX-770 improved growth in both CFTR G551D/KO and CFTR G551D/G551D ferrets despite large differences in exocrine pancreatic disease.
VX-770-mediated preservation of glycemic stability only in pancreatic sufficient CFTR
G551D/G551D ferrets We next determined whether VX-770-mediated protection of the exocrine pancreas rescues greater glycemic control in CFTR G551D ferrets. Destruction of the exocrine pancreas in CFTR KO/KO ferrets leads to spontaneous hyperglycemia and impaired postprandial glucose tolerance following their normal liquid diet at ~1 to 2 months of age (Fig. 4, A and B) during a period in which pancreatic inflammation peaks and islet mass is reduced (19) . As expected, CFTR G551D/KO ferrets with PI and maintained on VX-770 also underwent these glycemic disturbances, whereas CFTR G551D/G551D ferrets with PS did not (Fig. 4, A and B) . One CFTR G551D/KO animal fluctuated between PS and PI over this period, and its postprandial glucose was the lowest for that genotype (Fig. 4B) . By contrast, the one CFTR G551D/G551D ferret that later became pancreatic insufficient had the highest postprandial glucose of its group (Fig. 4B) . We additionally performed formal mixed-meal tolerance tests (MMTTs) on 3-to 4-month-old animals with a body surface area-normalized caloric intake from solid and liquid food. This analysis confirmed that glucose tolerance was normal in CFTR G551D/G551D ferrets with PS and maintained on VX-770, whereas it was abnormal in CFTR G551D/KO and CFTR G551D/G551D with PI despite sustained VX-770 treatment (Fig. 4, C to F) . Removal of CFTR G551D/KO ferrets from VX-770 for a 3-week period led to no change in glucose tolerance, as indexed by postprandial glucose excursions and AUC glucose (Fig. 4, C to D) . These findings are consistent with previous work in the CFTR knockout ferret model implicating destruction of the exocrine pancreas and islet remodeling as the primary determinants of impaired glycemic status in CF ferrets (19) .
Impact of CFTR function during early postnatal development on growth and survival
After establishing that in utero and early postnatal administration of VX-770 could increase survival and protect exocrine and endocrine pancreatic function, we evaluated the impact of VX-770 treatment cessation postnatally on the health of CFTR G551D/KO kits by terminating treatment of CFTR G551D/KO kits born to VX-770-treated jills at birth or at 7, 14, or 25 days after birth. In the case of CFTR G551D/KO kits, when VX-770 treatment continued only to birth or 7 days of age, growth rates did not differ from those of CFTR KO/KO kits (Fig. 5, A and B) . By contrast, when VX-770 treatment was continued to 14 or 25 days of age, their growth was substantially more rapid than that of CFTR KO/KO kits (Fig. 5, A and B) . Rescue of growth rates to that of wild-type animals ( Fig. 5A) , however, was achieved only when VX-770 treatment was maintained to 25 days. In addition, in CFTR G551D/KO kits, increase in survival required VX-770 treatment beyond 7 days of life, and the greatest benefit with respect to these parameters was in the 25-day group (Fig. 5C ). The primary reasons for early euthanasia of CFTR G551D/KO ferrets after termination of VX-770 administration were rectal prolapse, gut obstruction, and/or lung infection. Analysis of culturable bacteria in the lungs at the time of euthanasia identified bacterial taxa and titers similar to those found in CFTR KO/KO ferrets ( Fig. 5D ) (16, 17) . Gross lung pathology showed evidence of atelectasis and air trapping in the lung and mucus accumulation in the trachea (Fig. 5, E to G) . Histopathology demonstrated mucus accumulation in the large airways and submucosal glands (Fig. 5, H to Q, and fig.  S4 , A to H). Each of these pathologies has been observed in CFTR KO/KO ferrets (16, 17) . Cumulatively, these findings demonstrate that VX-770 treatment in utero and during the early postnatal period had therapeutic effects in CFTR G551D/KO ferrets. ; n = 8 CFTR
G551D/G551D
). (C) EL-1 concentrations for the indicated genotypes, treatment conditions, and age brackets. One animal in the CFTR G551D/G551D group exhibited PI after 2 months of age. For each genotype and age bracket, n = 6 to 20 animals. Significant differences in fecal EL-1 were observed between CFTR KO/KO versus CFTR G551D/G551D using two-way ANOVA and Bonferroni post hoc tests, **P < 0.01 and ***P < 0. ferret shown in the bottom panel of (B). The animal marked G551D/G551D + VX (PS)➔−VX (PI) was an adult pancreatic sufficient CFTR G551D/G551D ferret removed from VX-770 for 67 days. Arrows mark islets. Scale bars, 100 m (D) and 300 m (E).
Lung disease after cessation of VX-770 in adult CFTR G551D/KO ferrets To evaluate the rate of lung colonization in healthy adult CFTR G551D/KO ferrets, we used the cohort that was reared on both VX-770 and multiple antibiotics to ~8 months of age, during which glucose tolerance testing was performed free of potentially confounding effects of lung infection. The triple-antibiotic regimen was previously shown to prevent bacterial colonization of the CFTR KO/KO lung but not mucoinflammatory disease resulting from airway dehydration (20) . Lung infection in adult CFTR G551D/KO ferrets was monitored by serial bronchoscopy before and after termination of VX-770 and antibiotics (Fig. 6A) . The time to detection of culturable bacteria in the lung ranged from 51 to 134 days after VX-770 removal, and colony-forming unit (CFU) titers increased progressively with time (Fig. 6B) . CFTR G551D/KO ferrets removed from VX-770 eventually contracted terminal lung disease with mucus obstruction in the airways and submucosal glands (Fig. 6 , C to J), as previously observed in adult CFTR KO/KO ferret (17) .
Pancreatic and lung disease after cessation of VX-770 in adult CFTR G551D/G551D ferrets The majority of CFTR G551D/G551D ferrets were pancreatic sufficient while maintained on VX-770 (Fig. 3B) . To assess the effect of VX-770 removal from adult CFTR G551D/G551D ferrets, we reduced the VX-770 dose gradually by 2.5 mg/kg per week owing to concerns that severe acute onset of pancreatitis might be lethal. In addition to monitoring weight and fecal EL-1, we also assessed plasma pancreatic lipase (measure of pancreatitis). All the animals tested (n = 5) developed PI (EL-1 <200 g/g feces) within 3 weeks of complete VX-770 withdrawal ( fig. S5A ). Although plasma concentrations of pancreatic lipase remained relatively constant within each animal ( fig. S5B ), weight declined 10 to 20% from maximum for four of the animals during the 3-week period after complete VX-770 withdrawal ( fig. S5C) . Histopathology of pancreatic sufficient CFTR G551D/G551D ferrets removed from VX-770 demonstrated a conversion from normal pancreatic exocrine architecture to a fibrotic pancreas with plugging of the ducts and depletion of acinar cell mass (Fig. 3E, lower right) . MMTTs on these CFTR G551D/G551D before and after VX-770 withdrawal demonstrated a diabetic phenotype (blood glucose >200 mg/dl at 120 min) in only one of five ferrets (animal 4) at 1 month after cessation of VX-770 ( fig. S5, D and E) . By 3 to 5 months after cessation of VX-770, postprandial glucose in this animal (animal 4) normalized, but a third ferret (animal 3) progressed to a diabetic phenotype ( fig. S5, D and E) . are provided for the entire cohort (n = 7), i.e., including both animals with PS (n = 6) and PI (n = 1), and the single CFTR G551D/G551D ferret that developed PI. (F) Quantitation of blood glucose excursions for animals in (E), by AUC analysis. Significant differences in (A), (B), and (F) were determined by one-way ANOVA and Bonferroni post hoc tests, *P < 0.05, ***P < 0.001, ns, for comparison to CFTR KO/KO , and for (E) two-way ANOVA and Bonferroni post hoc tests, **P < 0.01, ***P < 0.001 for comparison of the complete CFTR G551D/G551D and CFTR WT/WT cohorts to the CFTR KO/KO group. In all graphs, data represent the means ± SEM.
Progression of lung disease in these five CFTR G551D/G551D ferrets after VX-770 withdrawal was assessed by bronchoscopy and lung histopathology at the time of declining health. The average culturable bacteria (CFU) in the BALF before stopping VX-770 was 73 ± 63 CFU/ml (n = 4, ±SEM; range, 0 to 255 CFU/ml; one bronchoscopy could not be obtained). At 1 to 2 months after complete termination of VX-770, follow-up BALF bacterial titers in these animals averaged 1891 ± 821 CFU/ml (n = 5, ±SEM; range, 0 to 4366 CFU/ml). Only one animal did not culture bacteria in the BALF after termination of VX-770, and titers in the others exceeded 1000 CFU/ml (table S1). Two of these animals (animals 2 and 3) were euthanized for failure to thrive, and lung histopathology in animal 3 (Fig. 7, A to F) and animal 2 Log-rank (Mantel-Cox) test was used to assess significance of differences in survival between days 0 and 7 versus day 14 (P = 0.0009 and P = 0.0088, respectively) and between days 0 and 7 versus day 25 (P = 0.0004 and P = 0.0010, respectively). CFTR KO/KO (n = 11, days 11 to 21, P < 0.05), (ii) CFTR G551D/KO 0 days (n = 7, days 11 to 21, P < 0.05), (iii) CFTR G551D/KO 7 days (n = 5, days 15 to 21, P < 0.05), (iv) CFTR G551D/KO 14 days (n = 8, day 21, P < 0.01), and (v) CFTR G551D/KO 25 days (n = 6, all days were not significant). For CFTR KO/KO versus (i) CFTR G551D/KO 0 days (all days were not significant),
(ii) CFTR G551D/KO 7 days (all days were not significant), (iii) CFTR G551D/KO 14 days (days 12 to 21, P < 0.05), and (iv) CFTR G551D/KO 25 days (days 10 to 21, P < 0.05).
( Fig. 7 , G to P) showed predominantly distal airway and alveolar disease dominated by neutrophil infiltration. However, the rapid decline of animal 2 after cessation of VX-770 was accompanied by the mucus occlusion of one lobe (Fig. 7 , G, H, and K to M). Although the timing of terminal disease onset was variable across subjects, VX-770 offered protection from bacterial infections and lung pathologies in CFTR G551D/G551D ferrets. Several CFTR G551D/KO and CFTR G551D/G551D ferrets were euthanized while maintained on VX-770 to evaluate whether treatment prevented lung disease. Histopathology of CFTR G551D/KO ferrets demonstrated single distal airways in most lobes with intermixed cellular debris and neutrophils ( fig. S6, A to F) . In contrast, lung histopathology of CFTR G551D/G551D ferrets was normal and submucosal glands lacked mucus accumulation (figs. S6, G to I, and S4, I to P). These findings suggest that CFTR G551D/G551D ferrets have sufficient CFTR expression to maintain normal lung clearance and innate immunity while on VX-770.
VX-770 cessation promotes CFTR
G551D/KO lung inflammation Mucus accumulation and inflammation are hallmarks of the CF lung (21, 22) , and in CFTR KO/KO ferrets, mucoinflammatory lung disease can occur with and without bacterial infection depending on the antibiotic treatment regimen used (17, 20) . We reasoned that termination of VX-770 treatment in CFTR G551D ferrets would enhance markers of CF lung disease, such as mucus accumulation and inflammation in the lung. To this end, we performed quantitative proteomics on BALF from three CFTR G551D/KO ferrets before and 1 month after cessation of VX-770. Results from this analysis identified 239 proteins, of which 62 were significantly changed (P < 0.05) after removal of VX-770 ( Fig. 8A and sheet A in data file S1). Sixty-five percent of the differentially regulated proteins were increased in the BALF after VX-770 withdrawal. Proteins of lung epithelial origin that were shown to be significantly (P < 0.05) increased in the BALF after VX-770 withdrawal included mucin 5AC (MUC5AC) and kallikrein 1 (KLK1), a serine protease known to be associated with lung disease (23), whereas significantly (P < 0.05) decreased proteins included submucosal gland-secreted MUC5B and lactotransferrin (LTF) and surface airway club cell-secreted secretoglobin family 1A member 1 (SCGB1A1) (Fig. 8A) . Pathway analysis using ReactomePA also dem onstrates significant enrichment (adjusted P value, 3.2 × 10 −35 ) in BALF proteins associated with neutrophil degranulation (R-HSA-6798695) (Fig. 8, A and B) .
Pathway analysis of the proteomics data using Medical Subject Headings (MeSH) supported a rise in lung disease after VX-770 withdrawal, with enriched disease pathway including lung disease, CF, pneumonia, and infection, among others ( Fig. 8C and sheet B in data file S1). Similarly, Ingenuity Pathway Analysis (IPA) confirmed enrichment in canonical pathways relating to acute phase response signaling, liver X receptor-retinoid X receptor (LXR/RXR), complement system, and phagosome maturation, among others ( Fig. 8D and sheet C in data file S1). IPA diseases and functions pathways also demonstrated enrichment in processes involved in cellular infiltration of the lung, inflammation of the lung, and leukocyte migration and an enhancement of pathways (z score >2) involved in quantity of leukocytes, quantity of phagocytes, and quantity of antigenpresenting cells (Fig. 8E and sheet D in data file S1). Each of these analyses supports enhanced lung disease and inflammation after withdrawal of VX-770 from CFTR G551D/KO ferrets.
DISCUSSION
We have created a CFTR G551D ferret model that exhibits multiorgan disease and is responsive to the CFTR potentiator VX-770. We showed that VX-770 can be administered to pregnant ferrets to protect animals from developmental abnormalities caused by in utero CFTR defects, including the prevention neonatal mortality associated with MI. The G551D ferret response to VX-770 is remarkably similar to that of patients with CF (8), including partial recovery of pancreatic function, slowed lung disease, reduced infections, and improved weight gain. Furthermore, withdrawal of VX-770 from CFTR G551D ferrets leads to emergence of multiorgan disease similar to that observed in CFTR KO/KO ferrets (15) (16) (17) (18) , and although there is little comparable information in CFTR G551D patients, there is one case study reporting the reemergence of lung disease upon VX-770 withdrawal (24) .
Initial characterization of this model revealed similarity to the human condition, therefore providing a path to probe the relationship between CFTR function during development and early life and disease severity and progression later in life. For example, the in utero data suggest that there may be a window during development [E28 to P25 (postnatal day 25)] when CFTR function is critical for postnatal health and survival of CF ferrets. The similar postnatal growth rates observed for weaning pancreatic insufficient CFTR G551D/KO and pancreatic sufficient CFTR G551D/G551D ferrets maintained on VX-770 suggest that factors extrinsic to the pancreas may play a key role in CF health early in life and is consistent with data from patients with CF (8) . In addition, we observed a clear association between abnormal glucose tolerance and exocrine pancreas insufficiency in both CFTR G551D/G551D and CFTR G551D/KO ferrets, consistent with exocrine pancreatic disease early in life being associated with a higher incidence of CF-related diabetes in humans (25) . However, the variable and somewhat less severe postprandial glucose phenotypes in adult CFTR G551D/G551D removed from VX-770 were unexpected, with only one of the four surviving animals progressing to a CF-related diabetes phenotype at 3 to 5 months after cessation. This model is expected to prove useful for studying CFTR functions in the pancreas and the mechanisms by which age-dependent pancreatic remodeling events in CF lead to failure of islet function.
These data not only confirm the in vitro and/or in vivo efficacy of a CFTR modulator on airway and intestinal epithelia but also provide the first direct evidence that VX-770 increases CFTR function in pancreatic epithelial cells. The hypomorphic nature of the ferret CFTR G551D allele likely played a key role in the extent of VX-770-mediated protection of CF ferrets from lung disease, MI, and exocrine pancreatic dysfunction. The low expression of the knock-in allele is likely due to the presence of a neomycin expression cassette in the adjacent intron of the targeted locus. The LoxP sites flanking the neomycin have not been activated in the ferrets studied here. The current dosing regimen led to ferret VX-770 exposures similar to those associated with maximal efficacy in patients with the CFTR G551D mutation (26) . Despite the ~50% reduction in mRNA and protein expression from the CFTR G551D knock-in allele, VX-770 exposures resulted in partial to complete protection from disease in the various organs studied in CFTR G551D ferrets.
Data from humans possessing hypomorphic CFTR intronic splice variants suggest that ~8 to 12% normal CFTR transcript is sufficient to prevent disease (27) . On the basis of in vivo concentrations of VX-770 and the in vitro studies of epithelia from the CFTR G551D ferrets, the ferret model appears relatively consistent with human data. Future studies titrating VX-770 exposure and varying timing of administration will better elucidate the threshold amount of CFTR activity and treatment window necessary to prevent disease across organs in the ferret model. This study has some limitations. Despite improved availability of viable CFTR G551D ferrets due to VX-770 treatment, the size of cohorts for several of the more labor-intensive experiments and end points were resource-limited. With this in mind, longitudinal studies that use less invasive translational end points, such as nasal potential difference to assess CFTR function and spirometry to quantitatively measure lung disease progression, could provide outcomes closer to those assessed in patients with CF. Regional fluctuations in CF lung colonization over time can also make the use of bronchoscopic BALF collection less reproducible for quantifying bacterial load longitudinally in animals, despite controlling for this by sampling the same lobe; there are limited data in patients with CF to compare our experience. In addition, we did not investigate the presence of nonbacterial organisms in the lung. Thus, we cannot comment on the contribution of either fungal or viral infections in CFTR G551D ferret lung disease progression. Last, the in vivo dose-response relationship between VX-770 and
CFTR
G551D function was not fully explored in the present study; thus, it remains unknown whether optimal efficacy was achieved in all CF animals.
Fundamental questions remain regarding CF pathogenesis that cannot be easily addressed in humans. The current VX-770-responsive CFTR G551D model affords a pharmacological switch for selective activation and inactivation of CFTR function and provides a path to address many of these questions. For example, what is the critical window to rescue organ function, and at what point does organ damage become irreversible? Another key question is how well rescue of CFTR function during development and early postnatal periods protects against initiation of lung disease later in life. Furthermore, widespread use of the CF ferret model has previously been limited by the high rate of neonatal mortality and the laborintensive nature of rearing CF kits, two factors overcome by the G551D ferret model. The implications of this study for human therapy remain to be determined because examples of in utero treatment of a genetic disease are rare (28) . However, the findings from this study emphasize the importance of early interventions in the treatment of CF and offer a model to understand the relation between CFTR function and disease pathophysiology and progression, which may inform the development and application of future CF therapies. 
MATERIALS AND METHODS
Study design
The objectives of this study were to create a CFTR G551D ferret model and to evaluate whether VX-770 could protect animals from disease progression. In vitro end points were used to assess the extent to which VX-770 could potentiate CFTR G551D and included the use of intestinal organoids, freshly excised intestine, and polarized PDE. In vivo end points for assessing VX-770 action included the following: (i) in utero VX-770 treatment and assessment of the extent of protection from developmental abnormalities of the gut, pancreas, and male reproductive tract; (ii) sustained postnatal VX-770 treatment and assessment of growth, survival, exocrine pancreatic function, glucose intolerance, and lung colonization; and (iii) withdrawal of VX-770 during the early postnatal period or in adulthood and analysis of disease progression in the pancreas and lung. The primary data are reported in table S1.
Generation of CFTR
G551D ferrets using homologous recombination and somatic cell nuclear transfer The strategy used to generate the CFTR G551D ferret was the same as previously described for the CFTR KO ferret (29) . Targeting was initiated by infecting primary fetal ferret fibroblasts with rAAV harboring the G551D mutant exon 11, neomycin selection cassette, and flanking intronic homology (AAV2.G551D-TG; see fig. S1 ). On day 1 after infection, fibroblasts were serially diluted and cultured with G418 (300 g/ml) for 15 days. G418-resistant clones were screened for homologous recombination PCR (see fig. S1 ); clones positive for both the left and right arms of the predicted homologous recombination event were expanded and animals were cloned by serial somatic cell nuclear transfer (29) . The reconstructed embryos were then transferred into pseudopregnant recipient jills. The genotype of each G551D-targeted ferret founder was confirmed by Southern blotting.
Rearing of ferrets
All animal experimentation was approved by the Institutional Animal Care and Use Committee. VX-770 (20 mg/kg body weight, formulated in elemental liquid diet EleCare, Abbott) was administered orally once a day to pregnant jills, starting on day 28 of gestation (parturition typically occurs on day 42 of gestation). Newborn CF kits were gavaged daily with VX-770 (5 mg/kg) formulated in EleCare or EleCare plus the laxative NuLYTELY (Braintree Laboratories). The dose was increased to 10 mg/kg daily at 14 days of age and maintained at that dose thereafter. CF ferrets used for glucose tolerance testing were also maintained on three antibiotics from birth, as previously described (19) , to ensure that the lungs would not be infected. These animals were later withdrawn from antibiotics and VX-770 to assess progression of lung disease.
Histopathology
At necropsy, the lung, trachea, pancreata, vas deferens, and epididymis were fixed in 10% neutral buffered formalin, routinely processed, embedded in paraffin, and sectioned at 4 m. All sections were stained with H&E, and select sections were stained with Periodic Acid-Schiff for light microscopy. A board-certified veterinary pathologist performed the histopathological examination.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software. For all experiments, data are expressed as means ± SEM. The statistical significance of the observed differences was calculated using oneor two-way ANOVA with Bonferroni post hoc tests. Results were considered significant when P < 0.05. Proteomics data were evaluated using Scaffold Q+S version 4.7 (Proteome Software) at 0% false discovery rate and with statistical testing accompanying the Scaffold algorithm. Experiments were not blinded or randomized.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/11/485/eaau7531/DC1 Materials and Methods Fig. S1 . Generation of G551D-CFTR ferrets using AAV-directed mutagenesis and somatic cell nuclear transfer. Fig. S2 . Forskolin-induced swelling of intestinal organoids and Isc of intestinal epithelia and PDE. Fig. S3 . Expression of CFTR mRNA in the fetal intestine and pancreas. Fig. S4 . Lung histology of all lobes from a CFTR G551D/KO ferret removed from VX-770 and a CFTR G551D/G551D ferret maintained on VX-770. Table S1 . Primary data (provided as a separate Excel file). Data file S1. Proteomics data (provided as a separate Excel file). Data file S2. RNA tissue quantification and smFISH probe maps.
References (30) (31) (32) (33) (34) (35) 
